Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genprex, Inc. (NASDAQ: GNPX) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a clinical-stage gene therapy company, Genprex uses these filings to describe its oncology and diabetes pipelines, financing activities, and Nasdaq listing status.
Key documents include registration statements such as Form S-1 and Form S-3, where Genprex outlines its business overview, risk factors, and details of equity offerings and warrant structures. These filings describe the company’s focus on Reqorsa Gene Therapy (quaratusugene ozeplasmid) for non-small cell and small cell lung cancer, the Oncoprex Delivery System, and the GPX-002 diabetes gene therapy program using AAV delivery of Pdx1 and MafA genes to the pancreas.
Investors can also review Form 8-K current reports that document material events. Recent 8-Ks discuss registered direct offerings and concurrent private placements, at-the-market program updates, new patents and patent intentions around Reqorsa combinations with PD-1 and PD-L1 antibodies, additions of clinical trial sites for Acclaim-1 and Acclaim-3, and communications with Nasdaq regarding minimum bid price and stockholders’ equity requirements.
On Stock Titan, AI-powered tools summarize lengthy prospectuses and current reports, helping readers quickly identify sections related to gene therapy mechanisms, clinical trial design, regulatory designations, and capital-raising terms. As new filings appear on EDGAR, they are reflected here in near real time, giving users an organized view of Genprex’s regulatory history, financing transactions, and disclosures relevant to GNPX stock.
Genprex, Inc. reported that it has added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of lead drug candidate REQORSA Gene Therapy in lung cancer. The company also plans to add and open additional Acclaim trial sites over the coming months to reach more patients and speed enrollment.
Acclaim-1 is a Phase 1/2 trial in late-stage non-small cell lung cancer with EGFR mutations combining REQORSA with Tagrisso, with a Phase 2a expansion targeting about 33 patients and an interim analysis after 19 patients, which Genprex currently expects to fully enroll in the first half of 2026; the trial has FDA Fast Track Designation. Acclaim-3 is a Phase 1/2 trial in extensive stage small cell lung cancer combining REQORSA with Tecentriq as maintenance therapy, with Phase 2 expansion for about 50 patients and an interim analysis after the 25th patient reaches 18 weeks of follow-up, also expected to reach that enrollment milestone in the first half of 2026, and benefits from FDA Fast Track and Orphan Drug Designations.
Genprex, Inc. reported that the U.S. Patent and Trademark Office has granted a patent covering the use of its lead drug candidate, REQORSA Gene Therapy (quaratusugene ozeplasmid), in combination with PD‑L1 antibodies such as Tecentriq, with protection extending through 2037. This patent is intended to secure exclusivity for this cancer treatment combination by preventing competitors from making, using or selling the same drug combination.
The company highlighted that REQORSA is being studied in the Acclaim‑3 Phase 1/2 trial as maintenance therapy with Tecentriq for patients with extensive stage small cell lung cancer. Phase 1 dose escalation showed REQORSA was generally well tolerated with no dose‑limiting toxicities, and the Phase 2 expansion is expected to enroll about 50 patients. The primary goal is to assess 18‑week progression‑free survival, with an interim analysis planned after the 25th patient reaches 18 weeks of follow up in the first half of 2026. Acclaim‑3 is supported by FDA Fast Track and Orphan Drug designations.
Genprex, Inc. filed a Form S-8 registering 130,000 shares of common stock issuable under its 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).
The registered amount gives effect to the 1-for-50 reverse stock split effective October 21, 2025 and follows stockholder approval at the annual meeting held August 15, 2025. Prior S-8 registrations are incorporated by reference, and previously registered shares were adjusted for the 1-for-50 split and the 1-for-40 reverse split effective February 2, 2024.
Genprex, Inc. (GNPX) filed its Q3 2025 10‑Q, reporting continued operating losses and active financing to fund clinical programs. The company posted a Q3 net loss of
Liquidity: Cash and cash equivalents were
Capital structure: Shares outstanding were 1,004,247 as of September 30, 2025; a 1‑for‑50 reverse split was completed on October 21, 2025. An ELOC derivative liability of
Genprex, Inc. filed a prospectus supplement for an at‑the‑market offering of up to $11,495,368 of common stock under its Sales Agreement with H.C. Wainwright & Co., to be sold from time to time.
The company updated its public float to $81.7 million as of November 7, 2025, calculated from 1,944,732 shares held by non‑affiliates at $42.00 (the October 15, 2025 closing price), and stated it is no longer subject to General Instruction I.B.6 sales limitations. Through the date hereof, it has sold 492,508 shares under the Sales Agreement pursuant to prior prospectuses. The supplement also reflects a 1‑for‑50 reverse stock split effective October 21, 2025. Genprex’s common stock trades on Nasdaq as “GNPX”; the last reported sale price on November 10, 2025 was $4.00 per share.
Genprex (GNPX) reported an intellectual property update. The company announced that the European Patent Office communicated its intent to grant a patent covering the use of REQORSA Gene Therapy (quaratusugene ozeplasmid) with PD-1 antibodies for treating cancer.
If granted, this patent would build on existing protection for REQORSA in combination with PD-1 antibodies already granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. Genprex notes REQORSA is being developed alongside approved cancer drugs for lung cancer, with preclinical studies indicating complementarity with targeted therapies and immunotherapies.
Genprex (GNPX) entered into a registered direct offering of 377,780 shares at $9.00 per share, alongside a concurrent private placement of warrants exercisable for up to 755,560 shares at an exercise price of $8.75. The transaction is expected to close on or about October 29, 2025, subject to customary conditions.
The company expects approximately $3.0 million in net proceeds from the share sale, excluding any warrant exercises. If the private warrants are fully exercised, Genprex would receive additional gross proceeds of about $6.6 million. Proceeds are earmarked for working capital and general corporate purposes.
Placement agent compensation includes a 7.0% cash fee and a 1.0% management fee, expense reimbursements, and 22,667 placement agent warrants at a $11.25 exercise price. Genprex agreed to a 5‑day issuance/filing standstill and a 1‑year prohibition on variable‑rate issuances, with exceptions for its ATM and equity line. The company will file an S‑1 for warrant share resale within 30 days and target effectiveness within 60 days (or 90 days if fully reviewed). A beneficial ownership cap limits exercises to 4.99%, adjustable up to 9.99%.
Genprex, Inc. priced a primary offering of 377,780 shares of common stock at $9.00 per share, for gross proceeds of $3,400,020. After placement agent fees of $0.63 per share, the company expects proceeds before expenses of $3,162,018.60. Net proceeds are estimated at approximately $3.0 million, earmarked for working capital and general corporate purposes. Shares outstanding were 1,254,061 before the offering and are expected to be 1,631,841 immediately after.
In a concurrent private placement, purchasers will receive warrants to buy up to 755,560 shares at an exercise price of $8.75 per share; these warrants and their underlying shares are not registered here. Genprex will also issue placement agent warrants for up to 22,667 shares at $11.25 per share. The company recently effected a 1‑for‑50 reverse stock split (October 21, 2025) following a 1‑for‑40 split in 2024, and continues to work toward Nasdaq listing compliance. The common stock trades on Nasdaq under “GNPX”.
Genprex, Inc. (GNPX) reported that its research collaborators presented positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid) in ALK-EML4 positive non-small cell lung cancer at the 2025 AACR-NCI-EORTC conference in Boston.
The study showed REQORSA can overexpress the tumor suppressor gene TUSC2 in ALK+ NSCLC cell lines and patient-derived organoids, inducing apoptosis, including in cells resistant to alectinib. Combining REQORSA with alectinib further increased apoptosis, and in a mouse xenograft model the combination improved survival versus control. The Company stated these results support a potential future clinical trial in ALK-positive lung cancer.
Genprex, Inc. (GNPX) entered a financing on October 23, 2025. The company agreed to sell 243,622 registered shares at $11.21 per share in a registered direct offering and, in a concurrent private placement, issue warrants exercisable for up to 487,244 shares at an $11.00 exercise price.
Genprex expects approximately $2.3 million in net proceeds from the registered direct, excluding any warrant exercise proceeds. If the private warrants are exercised in full, the company would receive approximately $5.4 million in additional gross proceeds. The company plans to use proceeds for working capital and general corporate purposes.
Separately, Genprex noted Nasdaq listing matters. A one-for-fifty reverse stock split was implemented on October 21, 2025 to address the $1.00 minimum bid price requirement, which must be maintained for 10 consecutive business days. The Nasdaq Hearings Panel granted an exception through October 31, 2025, with potential discretion to extend to February 9, 2026.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
